IFNG and neoplasm: A recent multi-center phase 1 trial used a chemically activatable IL-12 gene delivered into the tumor site, where IL-12 expression triggered by the drug veledimex achieved conversion of an immunologically “cold” TME to an inflamed “hot” TME with increased influx of IFN-γ–producing T cells (120).